PREPARATION AND DISTRIBUTION OF RESEARCH DRUG PRODUCTS
ID: 75N95024R00003Type: Presolicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIDABethesda, MD, 20892, USA

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH (AN11)

Original Source

https://sam.gov/opp/fac5db56c40c488aa9a78aefdda2db42/view
Timeline
    Description

    The National Institutes of Health (NIH), specifically the National Institute on Drug Abuse (NIDA), is seeking proposals for the "Preparation and Distribution of Research Drug Products" under solicitation number 75N95024R00003. The primary objective of this procurement is to acquire, analyze, create, and distribute a variety of drug compounds essential for drug abuse and addiction research, including controlled and uncontrolled substances, while ensuring compliance with DEA regulations. This contract, structured as an indefinite delivery, indefinite quantity (IDIQ) agreement for a five-year period, aims to enhance research capabilities in the field of drug abuse, with proposals due by November 15, 2024, at 1:00 PM (Eastern Time). Interested parties should contact Scott Duernberger at scott.duernberger@nih.gov or Josh Lazarus at josh.lazarus@nih.gov for further information.

    Files
    Title
    Posted
    Amendment 01.pdf
    The document is an amendment to solicitation 75N95024R00003, issued by the National Institute on Drug Abuse (NIDA). It primarily serves to respond to questions raised by potential offerors regarding proposal requirements. The amendment clarifies that the Technical Proposal is limited to 200 pages, excluding specific introductory and supplementary elements. The document also confirms that a certification for cost or pricing data is not necessary due to expected price competition and specifies that all mandatory qualification criteria must be met upon receipt of the Technical Proposals. A critical detail includes the requirement that offerors must demonstrate access to a DEA-approved secure storage facility for refrigeration of an inventory of around 300 stock items at the time of submission. The proposal due date remains unchanged, set for November 5, 2024. This document emphasizes transparency in the federal procurement process while ensuring compliance with regulatory requirements necessary for contract bidding.
    Amendment 02.pdf
    The document is an amendment to a solicitation by the National Institute on Drug Abuse (NIDA) regarding a Request for Proposals (RFP) referenced as 75N95024R00003. Its primary purpose is to correct the due date for proposals, which remains unchanged as November 15th, 2024, at 1:00 PM (Eastern Time). The amendment outlines the procedures for potential offerors to acknowledge receipt of this change and emphasizes that all other terms and conditions of the solicitation remain intact. It is critical for respondents to confirm their understanding of the amendment, either through their proposals or via separate communication. The document reiterates the need for timely acknowledgment to avoid any potential rejection of offers. Overall, this amendment serves to clarify administrative aspects of the RFP process while ensuring compliance with procurement protocols.
    Solicitation_75N95024R00003_F.pdf
    The National Institute on Drug Abuse (NIDA) has issued Request for Proposal (RFP) No. 75N95024R00003 for the "Preparation and Distribution of Research Drug Products". The RFP invites proposals from qualified businesses with a submission deadline of November 15, 2024. The resulting contract is expected to incorporate an indefinite delivery, indefinite quantity (IDIQ) structure for a five-year period, allowing for cost reimbursement and/or fixed-price task orders based on NIDA's programmatic needs. Key focuses of the project will be acquiring, analyzing, creating, regulating, and distributing a variety of drug compounds essential for drug abuse research. All offerors are required to maintain active registration in the System for Award Management (SAM) and adhere to federal acquisition regulations. Proposals must be submitted electronically according to the guidelines stated in the attached documentation. Essential reporting and compliance requirements are outlined, ensuring transparency and accountability throughout the contract period. The contract aims to bolster research capabilities addressing drug abuse and addiction through defined deliverables and adherence to protocols involving controlled substances.
    SSN_OTSB_Final.pdf
    The National Institute on Drug Abuse (NIDA) is seeking Capability Statements from Other Than Small Business (OTSB) organizations for the preparation and distribution of research drug products in response to solicitation No. 75N95024R00003, focusing on controlled and uncontrolled drug compounds. This notice aims to assess the availability and capability of potential vendors while gathering information on their qualifications related to the NAICS code 541715. Interested parties must submit relevant documentation by November 16, 2023, specifying their compliance with mandatory requirements and project tasks outlined in the notice.
    Similar Opportunities
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a contract to provide pharmacy and pharmaceutical oversight for clinical trials, both nationally and internationally. The primary objective of this contract is to ensure the integrity of study products, participant safety, and compliance with pharmacy and pharmaceutical regulations throughout various NIH-funded clinical trials. This opportunity is critical for maintaining high standards in public health research, as it encompasses a wide range of services including product management, regulatory document maintenance, and clinical laboratory testing. Proposals are due by January 17, 2025, with the contract expected to commence on April 1, 2026, and run through March 31, 2027, potentially extending through 2033. Interested parties can contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov for further information.
    Long Sequencing Kits
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) NIDA, is seeking qualified small businesses to provide Long Sequencing Kits as part of a Sources Sought notice. The primary objective of this procurement is to acquire kits that facilitate long read sequencing for analyzing biomarkers related to Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD), which are crucial for understanding disease progression and therapeutic efficacy. The kits must meet specific technical requirements, including compatibility with Nanopore PromethION 48 sequencers and the ability to generate substantial sequencing data in real-time. Interested parties must submit their capability statements to Andrea Clay at amcgee@nida.nih.gov by December 31, 2024, at 12:00 PM Eastern Time, as this notice is strictly for research and information purposes and does not obligate the government to award a contract.
    Single-plex NULISApcr Absolute Quantification Assay of HDGFL2 in Plasma Samples
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is soliciting proposals for the development of a single-plex NULISApcr absolute quantification assay to measure HDGFL2 levels in plasma samples, linked to TDP-43 dysfunction associated with Alzheimer’s Disease and Related Dementias (ADRD). The project aims to establish a biomarker for HDGFL2, which is crucial for advancing research and treatment in neurological disorders. The anticipated contract will be a firm fixed-price purchase order with a performance period of twelve months, and proposals must be submitted electronically to Emily Palombo at emily.palombo@nih.gov by 9:00 a.m. Eastern Daylight Time on December 23, 2024. Interested parties should ensure compliance with all relevant FAR provisions and include necessary certifications in their submissions.
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the 2026 DMID Omnibus Broad Agency Announcement (BAA) aimed at advancing research and development of medical countermeasures against antimicrobial-resistant pathogens and viruses with pandemic potential. The BAA encompasses two primary research areas: the development of therapeutics, vaccines, and diagnostics for antimicrobial-resistant bacterial and fungal pathogens, and the creation of direct-acting antivirals for viral families of pandemic potential. This initiative is critical for addressing public health challenges related to infectious diseases and enhancing biodefense capabilities. Proposals for Research Area 001 are due by February 21, 2025, while those for Research Area 002 are due by January 21, 2025. Interested parties can reach out to primary contact Swee L. Teo at teosl@niaid.nih.gov or 240-669-5173 for further information.
    In Vitro Assessments of Antimicrobial Activity
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for the In Vitro Assessments of Antimicrobial Activity program to support in vitro testing for evaluating the therapeutic potential of compounds against infectious diseases. This initiative aims to enhance the understanding and treatment of infectious diseases by providing efficient assessment tools integrated into the product development pipeline, focusing on various pathogens including bacteria, fungi, viruses, and challenging pathogens that require innovative culturing techniques. The RFP will be available online around December 30, 2024, and proposals must be submitted via the NIAID electronic Contract Proposal Submission (eCPS) platform; interested parties can contact Alexander Beraud at alexander.beraud@nih.gov or Brian Madgey at brian.madgey@nih.gov for further information.
    Genotyping Services
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for genotyping services to analyze 1,500 DNA samples related to Alzheimer's Disease and Related Dementias research. The selected contractor will perform microarray genotyping using Illumina Infinium Global Diversity + Neurobooster Arrays, ensuring quality control and timely reporting of results to support the National Institute on Aging's objectives in advancing research in this critical area. Proposals must be submitted electronically by 11:00 A.M. Eastern on December 27, 2024, to Hashim Dasti at hashim.dasti@nih.gov, with the anticipated award being a firm fixed-price purchase order for a period of twelve months after receipt of order. Interested parties should ensure compliance with all applicable federal regulations and provide evidence of their capability to fulfill the requirements outlined in the solicitation.
    cDNA-PCR Sequencing Kits for long-read sequencing.
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the procurement of cDNA-PCR Sequencing Kits for long-read sequencing, as part of a combined synopsis/solicitation. The primary objective is to acquire Promethion Flow Cell packs and sequencing kits to support high-throughput sequencing efforts aimed at advancing research on neurodegenerative diseases, particularly Alzheimer's disease. This procurement is crucial for the Center for Alzheimer’s Disease and Related Dementias (CARD) and is expected to facilitate the identification of causative genes and potential therapeutic targets. Interested vendors must submit their quotations by 5:00 p.m. Eastern Time on December 30, 2024, referencing Solicitation Number 75N95025Q00008, and can direct inquiries to Iris Merscher at iris.merscher@nih.gov or by phone at 301-827-2547.
    Brand Name Biological Product
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking quotes for a brand name biological product under solicitation number RFQ-NIAID-25-2251721. The procurement involves the acquisition of specific biological supplies, including various anti-human antibodies, to support the National Institute of Allergy and Infectious Diseases (NIAID) in its research efforts. These products are critical for advancing biomedical research and ensuring the availability of high-quality reagents for scientific studies. Interested vendors must submit their offers by December 22, 2024, at 10:00 AM EST, and can direct inquiries to Calvin Robinson at calvin.robinson@nih.gov.
    Globus Standard Subscription Renewal
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute on Drug Abuse (NIDA), is seeking to renew its Globus Standard Subscription through a non-competitive Request for Quotation (RFQ) to the University of Chicago - Globus. This procurement aims to secure essential cloud storage services that facilitate data management and collaboration for scientific developers and users, providing features such as unlimited managed endpoints and integration with Google Drive and Amazon S3. The subscription is critical for enhancing the National Center for Advancing Translational Sciences' (NCATS) capabilities in drug discovery and therapeutic development, ensuring compliance with federal security and privacy standards. Proposals are due by December 24, 2024, for a contract period from January 1, 2025, to December 31, 2025, with inquiries directed to Sarah Adan at sarah.adan@nih.gov or 301-480-5422.
    Access to the Florence electronic Trial Master File (eTMF) Platform- 12 Months Annual Subscription
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to procure a 12-month annual subscription to the Florence electronic Trial Master File (eTMF) platform. This non-competitive solicitation aims to secure a commercial item necessary for secure data storage and management for the Rare Disease Clinical Research Network (RDCRN) program, ensuring continuity and compliance with existing systems currently in use. Interested vendors must submit their quotations by 1:00 p.m. Eastern Time on December 24, 2024, referencing Solicitation Number 75N95025Q00050, and can direct inquiries to Samson Shifaraw at samson.shifaraw@nih.gov or by phone at 301-480-7153.